Core Viewpoint - Boston Scientific Corporation (BSX) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of 75 cents, a 33.9% increase year-over-year, surpassing both the Zacks Consensus Estimate and the company's own guidance range [1][3][11] Financial Performance - The first-quarter revenue reached 4.66billion,reflectinga20.91.58 billion, up 11.7% year-over-year, with notable contributions from Endoscopy (673million),Urology(633 million), and Neuromodulation (271million)[6]−Cardiovascularsegmentrevenuesreached3.09 billion, a 26.2% increase, with Cardiology business sales totaling 2.43billion,up31.22.87-$2.94 [9][10] - The second quarter of 2025 is projected to see revenue growth of 17.5-19.5% on a reported basis [10] Strategic Developments - Recent acquisitions include SoniVie Ltd. and Bolt Medical, which are expected to positively impact the company's growth trajectory [12]